Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders

• Main Authors: Maria Grazia Perrone, Antonella Centonze, Morena Miciaccia, Savina Ferorelli, Antonio Scilimati
• Format: Article
• Language: English
• Published: MDPI AG 2020-11-01
• Series: Molecules
• Subjects: major depression; bipolar disorder; schizophrenia; autism spectrum disorder; cyclooxygenase (COX) inhibitors
• Online Access: https://www.mdpi.com/1420-3049/25/22/5388

According to the World Health Organization, the major psychiatric and neurodevelopmental disorders include major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. The potential role of inflammation in the onset and progression of these disorders is increasingly being studied. The use of non-steroidal anti-inflammatory drugs (NSAIDs), well-known cyclooxygenase (COX) inhibitors, combined with first-choice specific drugs have been long investigated. The adjunctive administration of COX inhibitors to classic clinical treatments seems to improve the prognosis of people who suffer from psychiatric disorders. In this review, a broad overview of the use of COX inhibitors in the treatment of inflammation-based psychiatric disorders is provided. For this purpose, a critical analysis of the use of COX inhibitors in the last ten years of clinical trials of the major psychiatric disorders was carried out.